Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium, 55204-55205 [2018-23989]
Download as PDF
55204
Federal Register / Vol. 83, No. 213 / Friday, November 2, 2018 / Notices
Tomasetti, Inc., Washington, DC; Toyon
Research Corporation, Goleta, CA;
Transtecs Corporation, Arlington, VA;
Triton Systems, Inc., Chelmsford, MA;
Ultra Electronics Ocean Systems, Inc.,
Braintree, MA; UnderSea Sensor
Systems, Inc. (USSI), Columbia City, IN;
University of Florida Board of Trustees,
Gainesville, FL; University of Rhode
Island, Kingston, RI; Viasat, Inc.,
Carlsbad, CA; Visionary Products, Inc.
(dba VPI Technology Group), Draper,
UT; Welkins LLC, Downers Grove, IL;
Woods Hole Oceanographic Institution,
Woods Hole, MA; and World Wide
Technology, Maryland Heights, MO.
The general area of UTIC’s planned
activity is conducting research,
development and testing in cooperation
with the Government leading to
technology demonstrations in undersea
and maritime technology applications
and solutions through the following
technology areas: Sensors and Sonar;
Platform and Payload Integration;
Undersea Distributed Networked
Systems; Electronics/Optics/Materials;
Passive Sensing; Undersea Satellites;
Energy Storage and Release;
Virtualization; Machine Learning;
Threat Monitoring and Prediction;
Cooperative Force Torpedo Defense;
Undersea Warfare Analysis; MultiDomain Fusion; Electronic Warfare;
Distributed and Autonomous Sensors;
USW Weapons and Autonomous
Vehicles; Autonomy; Quantum
Computing; Bio-Inspired Sensors;
Environmental Sensing, Monitoring and
Prediction; In-Situ Energy Sources; and
Multi-Dimensional Display.
Suzanne Morris,
Chief, Premerger and Division Statistics Unit
Antitrust Division.
[FR Doc. 2018–23984 Filed 11–1–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on Corrosion Under Insulation
Notice is hereby given that, on
October 4, 2018, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Southwest Research Institute—
Cooperative Research Group on
Cooperative Research Group on
Corrosion Under Insulation (‘‘CUI–JIP’’)
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
VerDate Sep<11>2014
17:57 Nov 01, 2018
Jkt 247001
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, The Dow Chemical
Company, Freeport, TX, has been added
as a party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and CUI–JIP
intends to file additional written
notifications disclosing all changes in
membership.
On March 22, 2018, CUI–JIP filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on April 24, 2018 (83 FR 17851).
The last notification was filed with
the Department on September 6, 2018.
A notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 17, 2018 (83 FR
46972).
Suzanne Morris,
Chief, Premerger and Division Statistics Unit,
Antitrust Division.
[FR Doc. 2018–23988 Filed 11–1–18; 8:45 am]
activity of the group research project.
Membership in this group research
project remains open, and RIC-Americas
intends to file additional written
notifications disclosing all changes in
membership.
On April 30, 2014, RIC-Americas filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on June 9, 2014 (79 FR
32999).
The last notification was filed with
the Department on August 17, 2018. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on September 4, 2018 (83 FR
44904).
Suzanne Morris,
Chief, Premerger and Division Statistics Unit,
Antitrust Division.
[FR Doc. 2018–23983 Filed 11–1–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Medical Technology
Enterprise Consortium
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on ROS-Industrial ConsortiumAmericas
Notice is hereby given that on
September 28, 2018, Pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Southwest Research Institute—
Cooperative Research Group on ROSIndustrial Consortium-Americas (‘‘RICAmericas’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Stratasys, Inc., Eden
Prairie, MN, and Cognex Corporation,
Natick, MA, have withdrawn as parties
to this venture.
No other changes have been made in
either the membership or planned
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Notice is hereby given that, on
October 12, 2018, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Medical Technology Enterprise
Consortium (‘‘MTEC’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, 8i Labs, Inc., Los
Angeles, CA; Adaptive Phage
Therapeutics, Inc. (Aphage),
Gaithersburg, MD; Aleo BME, Inc., State
College, PA; American Defense
International (ADI), Washington, DC;
Aptima, Inc., Woburn, MA; Atlantic
Diving Supply, Inc. (ADS), Virginia
Beach, VA; Benchmark Electronics, Inc.,
Scottsdale, AZ; BioMojo LLC, Cary, NC;
BioSpyder Technologies, Inc., Carlsbad,
CA; Brain Mapping Foundation, West
Hollywood, CA; Brain Power, LLC,
Cambridge, MA; BrainScope Company,
Inc., Bethesda, MD; CAE Healthcare,
Inc., Sarasota, FL; Carmell Therapeutics
Corporation, Pittsburgh, PA; Case
Western Reserve University, Cleveland,
OH; Cell Guidance Systems Ltd.,
E:\FR\FM\02NON1.SGM
02NON1
55205
Federal Register / Vol. 83, No. 213 / Friday, November 2, 2018 / Notices
Cambridge, UK; Clear Scientific, LLC,
Cambridge, MA; Cornerstone
Government Affairs, Inc., Washington,
DC; DePuy Synthes Products, Inc.,
Raynham, MA; Dignitas Technologies,
Orlando, FL; ECM Therapeutics, Inc.,
Warrendale, PA; ElMindA Ltd.,
Herzliya, Israel; Family Health
International DBA FHI 360, Durham,
NC; Hypatia Project, Reston, VA;
Institutes for Behavior Resources, Inc.
(IBR), Baltimore, MD; Integrated
MicroSciences, LLC, Frederick, MD; J.
Craig Venter Institute (JCVI), Rockville,
MD; KaloCyte, Inc., St. Louis, MO;
Lieber Institute, Inc., Baltimore, MD;
NanoDirect, LLC, Baltimore, MD;
OXYVITA, Inc., Middletown, NY;
Parsons Government Services, Inc.,
Pasadena, CA; Protocentral, Inc.,
Woburn, MA; Q2Pharma, Haifa, Israel;
RAIN Scientific, Inc., Asheville, NC;
Rehat, LLC, Pittsburgh, PA; Research
Foundation for Mental Hygiene, Inc.
(NYSPI), New York, NY; Responde2
Corporation, Mountain View, CA; Saint
Barnabas Medical Center (SBMC),
Livingston, NJ; San Diego Blood Bank,
San Diego, CA; SmartMD Systems, Inc.,
Manchester Center, VT; Sonica LLC,
Evanston, IL; Spire, San Francisco, CA;
Syracuse University, Syracuse, NY; The
Charles Stark Draper Laboratory, Inc.
(Draper), Cambridge, MA; The
University of Arizona, Defense and
Security Research Institute (DSRI),
Tucson, AZ; Trauma Insight, LLC, San
Antonio, TX; Trustees of Boston
University, Boston, MA; University of
Central Florida Research Foundation,
Inc., Orlando, FL; University of
Houston—Cullen College of
Engineering, Houston, TX; Vivonics,
Inc., Bedford, MA; and Washington
State University, Pullman, WA; have
been added as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MTEC
intends to file additional written
notifications disclosing all changes in
membership.
On May 9, 2014, MTEC filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 9, 2014 (79 FR 32999).
The last notification was filed with
the Department on May 3, 2018. A
notice was published in the Federal
VerDate Sep<11>2014
17:57 Nov 01, 2018
Jkt 247001
Register pursuant to Section 6(b) of the
Act on June 19, 2018 (83 FR 28448).
Suzanne Morris,
Chief, Premerger and Division Statistics Unit
Antitrust Division.
Dated: October 24, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–24005 Filed 11–1–18; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2018–23989 Filed 11–1–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
The registrants listed below
have applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as bulk
manufacturers of various classes of
schedule I and II controlled substances.
SUMMARY:
The
companies listed below applied to be
registered as bulk manufacturers of
various basic classes of controlled
substances. Information on previously
published notices is listed in the table
below. No comments or objections were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
FR citation
Chemtos,
83 FR 37520
LLC.
Johnson
83 FR 34880
Matthey Inc.
AMRI
83 FR 38179
Rensselaer,
Inc.
Published
August 1,
2018.
July 23,
2018.
August 3,
2018.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of these registrants to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each of the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed companies.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 2, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of registration.
Company
Bulk Manufacturer of Controlled
Substances Application: Janssen
Pharmaceuticals, Inc.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
September 13, 2018, Janssen
Pharmaceuticals, Inc., Buildings 1–5 &
7–14, 1440 Olympic Drive, Athens,
Georgia 30601 applied to be registered
as a bulk manufacturer of the following
basic classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
Methylphenidate ...............
Hydromorphone ................
Hydrocodone ....................
Oripavine ..........................
Thebaine ...........................
Tapentadol ........................
1724
9150
9193
9330
9333
9780
II
II
II
II
II
II
E:\FR\FM\02NON1.SGM
02NON1
Agencies
[Federal Register Volume 83, Number 213 (Friday, November 2, 2018)]
[Notices]
[Pages 55204-55205]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23989]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical Technology Enterprise Consortium
Notice is hereby given that, on October 12, 2018, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical Technology
Enterprise Consortium (``MTEC'') has filed written notifications
simultaneously with the Attorney General and the Federal Trade
Commission disclosing changes in its membership. The notifications were
filed for the purpose of extending the Act's provisions limiting the
recovery of antitrust plaintiffs to actual damages under specified
circumstances.
Specifically, 8i Labs, Inc., Los Angeles, CA; Adaptive Phage
Therapeutics, Inc. (Aphage), Gaithersburg, MD; Aleo BME, Inc., State
College, PA; American Defense International (ADI), Washington, DC;
Aptima, Inc., Woburn, MA; Atlantic Diving Supply, Inc. (ADS), Virginia
Beach, VA; Benchmark Electronics, Inc., Scottsdale, AZ; BioMojo LLC,
Cary, NC; BioSpyder Technologies, Inc., Carlsbad, CA; Brain Mapping
Foundation, West Hollywood, CA; Brain Power, LLC, Cambridge, MA;
BrainScope Company, Inc., Bethesda, MD; CAE Healthcare, Inc., Sarasota,
FL; Carmell Therapeutics Corporation, Pittsburgh, PA; Case Western
Reserve University, Cleveland, OH; Cell Guidance Systems Ltd.,
[[Page 55205]]
Cambridge, UK; Clear Scientific, LLC, Cambridge, MA; Cornerstone
Government Affairs, Inc., Washington, DC; DePuy Synthes Products, Inc.,
Raynham, MA; Dignitas Technologies, Orlando, FL; ECM Therapeutics,
Inc., Warrendale, PA; ElMindA Ltd., Herzliya, Israel; Family Health
International DBA FHI 360, Durham, NC; Hypatia Project, Reston, VA;
Institutes for Behavior Resources, Inc. (IBR), Baltimore, MD;
Integrated MicroSciences, LLC, Frederick, MD; J. Craig Venter Institute
(JCVI), Rockville, MD; KaloCyte, Inc., St. Louis, MO; Lieber Institute,
Inc., Baltimore, MD; NanoDirect, LLC, Baltimore, MD; OXYVITA, Inc.,
Middletown, NY; Parsons Government Services, Inc., Pasadena, CA;
Protocentral, Inc., Woburn, MA; Q2Pharma, Haifa, Israel; RAIN
Scientific, Inc., Asheville, NC; Rehat, LLC, Pittsburgh, PA; Research
Foundation for Mental Hygiene, Inc. (NYSPI), New York, NY; Responde2
Corporation, Mountain View, CA; Saint Barnabas Medical Center (SBMC),
Livingston, NJ; San Diego Blood Bank, San Diego, CA; SmartMD Systems,
Inc., Manchester Center, VT; Sonica LLC, Evanston, IL; Spire, San
Francisco, CA; Syracuse University, Syracuse, NY; The Charles Stark
Draper Laboratory, Inc. (Draper), Cambridge, MA; The University of
Arizona, Defense and Security Research Institute (DSRI), Tucson, AZ;
Trauma Insight, LLC, San Antonio, TX; Trustees of Boston University,
Boston, MA; University of Central Florida Research Foundation, Inc.,
Orlando, FL; University of Houston--Cullen College of Engineering,
Houston, TX; Vivonics, Inc., Bedford, MA; and Washington State
University, Pullman, WA; have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MTEC intends to file additional
written notifications disclosing all changes in membership.
On May 9, 2014, MTEC filed its original notification pursuant to
Section 6(a) of the Act. The Department of Justice published a notice
in the Federal Register pursuant to Section 6(b) of the Act on June 9,
2014 (79 FR 32999).
The last notification was filed with the Department on May 3, 2018.
A notice was published in the Federal Register pursuant to Section 6(b)
of the Act on June 19, 2018 (83 FR 28448).
Suzanne Morris,
Chief, Premerger and Division Statistics Unit Antitrust Division.
[FR Doc. 2018-23989 Filed 11-1-18; 8:45 am]
BILLING CODE 4410-11-P